Literature DB >> 2452984

Human interferon as a therapeutic agent: a decade passes.

T C Merigan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2452984     DOI： 10.1056/NEJM198806023182208

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

Review 2.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

3.  A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).

Authors:  H C Lane; R T Davey; S A Sherwin; H Masur; A H Rook; J F Manischewitz; G V Quinnan; P D Smith; M E Easter; A S Fauci
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

4.  Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.

Authors:  P J Arroyo; J A Bash; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Accelerated tumor development in interferon-treated B6.C-Hyal-1 a mice.

Authors:  J De Maeyer-Guignard; E Lauret; L Eusèbe; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

6.  Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.

Authors:  J Punnonen; P K Heinonen; T Kuoppala; C T Jansen; R Punnonen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.